sirukumab
FDA rejects J&J’s treatment for rheumatoid arthritis
September 25, 2017Sales and Marketing Johnson & Johnson, biotech, drugs, pharma, pharmaceutical, sirukumab
Perhaps unsurprisingly, after the FDA’s advisory committee had voted 12-1 against approval of Johnson & Johnson’s drug, the FDA returned …
FDA turns down Janssen’s sirukumab for rheumatoid arthritis
August 3, 2017Sales and Marketing FDA, Janssen, drugs, life sciences, medicine, pharma, pharmaceuticals, rheumatoid arthritis, sirukumab
Janssen has announced that it has suffered a knockback to its plans to commercialise sirukumab in the US in the …
GSK/J&J release how their drug measures up against Humira
November 18, 2016Medical Communications, Research and Development GSK, Humira, Janssen, Johnson & Johnson, sirukumab
GlaxoSmithKline and Janssen, part of Johnson & Johnson, released the results of their two Phase III trials exploring treatment options …
GSK and J&J file rheumatoid arthritis treatment sirukumab in EU
September 13, 2016Manufacturing and Production, Sales and Marketing GSK, GlaxoSmithKline, Johnson & Johnson, rheumatoid arthritis, sarilumab, sirukumab
GlaxoSmithKline and partner Johnson & Johnson’s Janssen Biologics unit have filed for approval of rheumatoid arthritis (RA) treatment sirukumab in …
GSK, Janssen RA treatment meets co-primary endpoints in Phase III trial
June 9, 2016Research and Development GSK, Janssen, eular 2016, rheumatoid arthritis, sirukumab
GSK (LSE: GSK) and Janssen, a division of Johnson and Johnson, have announced data from a pivotal Phase III study …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
